TACI, isotype switching, CVID and IgAD

Immunologic Research

Volumn 38, Issue 1-3, 2007, Pages 102-111

  Castigli, Emanuela ^a   Geha, Raif S ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

APRIL; BAFF; CVID and IgAD; Immunodeficiency; Isotype switching; TACI

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; B CELL MATURATION ANTIGEN; B LYMPHOCYTE ANTIGEN; BRUTON TYROSINE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ALLELE; AUTOSOMAL DOMINANT DISORDER; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BACTERIAL INFECTION; CELL DIFFERENTIATION; CHROMOSOME REARRANGEMENT; CLASS SWITCH RECOMBINATION; COMMON VARIABLE IMMUNODEFICIENCY; CONFERENCE PAPER; DISEASE PREDISPOSITION; GENE; GENE EXPRESSION; GENOTYPE PHENOTYPE CORRELATION; GERMINAL CENTER; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; LYMPHOCYTE PROLIFERATION; MUTATION; PLASMA CELL; PREVALENCE; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSMEMBRANE ACTIVATOR AND CALCIUM MODULATOR AND CYCLOPHILIN LIGAND INTERACTOR GENE;

B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; B-LYMPHOCYTES; COMMON VARIABLE IMMUNODEFICIENCY; HUMANS; IGA DEFICIENCY; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN ISOTYPES; MUTATION; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 35348904427     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-007-8000-2     Document Type: Conference Paper

References (52)

1. Mackay F, Kalled SL. TNF ligands and receptors in autoimmunity: an update. Curr Opin Immunol 2002;14:783-90.
2. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231-64.
3. Bischof D, Elsawa SF, Mantchev G, Yoon J, Michels GE, Nilson A, Sutor SL, Platt JL, Ansell SM, von Bulow G, Bram RJ. Selective activation of TACI by syndecan-2. Blood 2006;107:3235-42.
4. Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals S, Hahne M, Spaargaren M, Medema J. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 2005;12:637-48.
5. Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner Q, Cachero T, Qiang F, Gorelik L, Kalled S, Acha-Orbea H, Rennert P, Tschopp J, Schneider P. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005;201:1375-83.
6. Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, Pantesco V, De Vos J, Jourdan E, Jauch A, Legouffe E, Moos M, Fiol G, Goldschmidt H, Rossi JF, Hose D, Klein B. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005;106:1021-30.
7. Schwaller J, Schneider P, Mhawech-Fauceglia P, McKee T, Myit S, Matthes T, Tschopp J, Donze O, Legal FA, Huard B. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B cell Lymphoma aggressiveness. Blood 2007;109:331-8.
8. Lopez-Fraga M, Fernandez R, Albar JP, Hahne M. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep 2001;2:945-51.
9. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, Scott ML. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001;293:2111-4.
10. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, McMillen S, Waggie K, Schreckhise RW, Shoemaker K, Vu T, Moore M, Grossman A, Clegg CH. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 2001;15:289-302.
11. Castigli E, Scott S, Dedeoglu F, Bryce P, Jabara H, Bhan AK, Mizoguchi E, Geha RS. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 2004;101:3903-8.
12. von Bulow GU, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997;278:138-41.
13. von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity 2001;14:573-82.
14. Yan M, Wang H, Chan B, Roose-Girma M, Erickson S, Baker T, Tumas D, Grewal IS, Dixit VM. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2001;2:638-43.
15. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003;18:279-88.
16. Hymowitz S, Patel D, Wallweber H, Runyon S, Yan M, Yin J, Shriver S, Gordon N, Pan B, Skelton N, Kelley R, Starovasnik M. Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J Biol Chem 2005;280:7218-27.
17. Ni C, Oganesyan G, Welsh K, Zhu X, Reed J, Satterthwait A, Cheng G, Ely K. Key molecular contacts promote recognition of the BAFF receptor by TNF receptor-associated factor 3: implications for intracellular signaling regulation. J Immunol 2004;173:7394-400.
18. Xia XZ, Treanor J, Senaldi G, Khare SD, Boone T, Kelley M, Theill LE, Colombero A, Solovyev I, Lee F, McCabe SRE, Miner K, Hawkins N, Guo J, Stolina M, Yu G, Wang J, Delaney J, Meng SY, Boyle WJ, Hsu H. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med 2000;192:137-43.
19. Jabara H, Laouini D, Tsitsikov E, Mizoguchi E, Bhan A, Castigli E, Dedeoglu F, Pivniouk V, Brodeur S, Geha R. The binding site for TRAF2 and TRAF3 but not for TRAF6 is essential for CD40-mediated immunoglobulin class switching. Immunity 2002;17:265-76.
20. Jabara HH, Geha RS. Jun N-terminal kinase is essential for CD40-mediated IgE class switching in B cells. J Allergy Clin Immunol 2005;115:856-63.
21. Ahonen C, Manning E, Erickson L, O'Connor B, Lind E, Pullen S, Kehry M, Noelle R. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat Immunol 2002;3:451-56.
22. von Bulow GU, Russell H, Copeland NG, Gilbert DJ, Jenkins NA, Bram RJ. Molecular cloning and functional characterization of murine transmembrane activator and CAML interactor (TACI) with chromosomal localization in human and mouse. Mamm Genome 2000;11:628-32.
23. Zhang X, Park C, Yoon S, Li L, Hsu Y, Ambrose C, Choi Y. BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors. Int Immunol 2005;17:779-88.
24. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, Noelle RJ. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004;199:91-8.
25. Castigli E, Wilson SA, Scott S, Dedeoglu F, Xu S, Lam KP, Bram RJ, Jabara H, Geha RS. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005;201:35-9.
26. Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 2004;173:2245-52.
27. Shulga-Morskaya S, Dobles M, Walsh ME, Ng LG, MacKay F, Rao SP, Kalled SL, Scott ML. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004;173:2331-41.
28. Geha RS, Jabara HH, Brodeur SR. The regulation of immunoglobulin E class-switch recombination. Nat Rev Immunol 2003;3:721-32.
29. He B, Qiao X, Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 2004;173:4479-91.
30. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-9.
31. Di Renzo M, Pasqui AL, Auteri A. Common variable immunodeficiency: a review. Clin Exp Med 2004;3:211-7.
32. Kokron CM, Errante PR, Barros MT, Baracho GV, Camargo MM, Kalil J, Rizzo LV. Clinical and laboratory aspects of common variable immunodeficiency. An Acad Bras Cienc 2004;76:707-26.
33. Schroeder HW Jr., Schroeder HW III, Sheikh SM. The complex genetics of common variable immunodeficiency. J Investig Med 2004;52:90-103.
34. Burrows PD, Cooper MD. IgA deficiency. Adv Immunol 1997;65:245-76.
35. Cunningham-Rundles C. Physiology of IgA and IgA deficiency. J Clin Immunol 2001;21:303-9.
36. Weston SA, Prasad ML, Mullighan CG, Chapel H, Benson EM. Assessment of male CVID patients for mutations in the Btk gene: how many have been misdiagnosed? Clin Exp Immunol 2001;124:465-9.
37. Eastwood D, Gilmour KC, Nistala K, Meaney C, Chapel H, Sherrell Z, Webster AD, Davies EG, Jones A, Gaspar HB. Prevalence of SAP gene defects in male patients diagnosed with common variable immunodeficiency. Clin Exp Immunol 2004;137:584-8.
38. Farrington M, Grosmaire L, Nonoyama S, Fischer S, Hollenbaugh D, Ledbetter J, Noelle R, Aruffo A, Ochs H. CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci USA 1994;91:1099-103.
39. Warnatz K, Bossaller L, Salzer U, Skrabl-Baumgartner A, Schwinger W, van der Burg M, van Dongen JJ, Orlowska-Volk M, Knoth R, Durandy A, Draeger R, Schlesier M, Peter HH, Grimbacher B. Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood 2006;107:3045-52.
40. Kralovicova J, Kusikova M, Buc M, Holomanova D, Sakalova A. [Frequency of HLA-A, HLA-B and HLA-Cw antigens in the Slovak population]. Bratisl Lek Listy 2000;101:24-7.
41. Islam KB, Baskin B, Nilsson L, Hammarstrom L, Sideras P, Smith CI. Molecular analysis of IgA deficiency. Evidence for impaired switching to IgA. J Immunol 1994;152:1442-52.
42. Wang Z, Yunis D, Irigoyen M, Kitchens B, Bottaro A, Alt FW, Alper CA. Discordance between IgA switching at the DNA level and IgA expression at the mRNA level in IgA-deficient patients. Clin Immunol 1999;91:263-70.
43. Asano T, Kaneko H, Terada T, Kasahara Y, Fukao T, Kasahara K, Kondo N. Molecular analysis of B-cell differentiation in selective or partial IgA deficiency. Clin Exp Immunol 2004;136:284-90.
44. Islam KB, Nilsson L, Sideras P, Hammarstrom L, Smith CI. TGF-beta 1 induces germ-line transcripts of both IgA subclasses in human B lymphocytes. Int Immunol 1991;3:1099-106.
45. Bonhomme D, Hammarstrom L, Webster D, Chapel H, Hermine O, Le Deist F, Lepage E, Romeo PH, Levy Y. Impaired antibody affinity maturation process characterizes a subset of patients with common variable immunodeficiency. J Immunol 2000;165:4725-30.
46. Levy Y, Gupta N, Le Deist F, Garcia C, Fischer A, Weill JC, Reynaud CA. Defect in IgV gene somatic hypermutation in common variable immuno-deficiency syndrome. Proc Natl Acad Sci USA 1998;95:13135-40.
47. Andersen P, Permin H, Andersen V, Schejbel L, Garred P, Svejgaard A, Barington T. Deficiency of somatic hypermutation of the antibody light chain is associated with increased frequency of severe respiratory tract infection in common variable immunodeficiency. Blood 2005;105:511-7.
48. Castigli E, Wilson S, Garibyan L, Rachid R, Bonilla F, Schneider L, Geha R. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005;37:829-34.
49. Salzer U, Chapel HM, Webster AD, Pan-Hammarstrom Q, Schmitt-Graeff A, Schlesier M, Peter HH, Rockstroh JK, Schneider P, Schaffer AA, Hammarstrom L, Grimbacher B. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005;37:820-8.
50. Reyes-Moreno C, Girouard J, Lapointe R, Darveau A, Mourad W. CD40/CD40 homodimers are required for CD40-induced phosphatidylinositol 3-kinase-dependent expression of B7.2 by human B lymphocytes. J Biol Chem 2004;279:7799-806.
51. Siegel R, Frederiksen J, Zacharias D, Chan F, Johnson M, Lynch D, Tsien R, Lenardo M. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000;288:2328-9.
52. Salzer U, Grimbacher B. TACItly changing tunes: farewell to a yin, yang of BAFF receptor and TACI in humoral immunity? New genetic defects in common variable immunodeficiency. Curr Opin Allergy Clin Immunol 2005;5:496-503.